ImmunityBio Inc (IBRX)

ImmunityBio's stock price has experienced significant fluctuations over the past six months. The stock was trading around $2.14 as of November 27, 2025, down nearly 20% over the past month and 17% year-to-date. Key events include the FDA approval of Anktiva in April 2024, which followed an initial rejection in May of the previous year. The Q3 2025 earnings report showed product revenue climbing, supported by stronger demand for Anktiva. In December 2024, ImmunityBio's shares plunged after a public offering. H.C. Wainwright reiterated a "Buy" rating on the stock, and BTIG initiated coverage with a "Buy" recommendation.

There is no specific indication of demand seasonality for ImmunityBio, Inc.'s products and services. Demand for its therapies is likely driven by ongoing medical needs rather than seasonal patterns. Recent reports indicate strong and growing demand for Anktiva, suggesting consistent need for its approved product.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccines for life-threatening diseases. The company operates within the Healthcare sector, specifically in Biotechnology: Biological Products. ImmunityBio harnesses the immune system through platforms like antibody-cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. Key products include Anktiva (N-803) for bladder cancer, T-cell therapies for solid tumors and hematologic malignancies, infectious disease vaccines including a COVID-19 vaccine candidate, PD-L1 t-haNK, and Aldoxorubicin.

ImmunityBio, Inc. is headquartered in San Diego, California, with additional operations in Culver City, California. The company has expanded its manufacturing capacity with a facility in western New York, and also has existing manufacturing capacity in the U.S., South Africa, and Botswana through strategic collaborators. ImmunityBio also has operations in Italy and South Korea, with key revenue primarily generated from the United States.

ImmunityBio's brand reputation has been influenced by both challenges and successes. The FDA approval of Anktiva significantly bolstered the company's standing. Positive clinical trial results for various cancers further enhance its reputation. The initial FDA rejection of Anktiva negatively impacted its reputation, but the company successfully addressed these concerns and gained approval.

ImmunityBio has a mixed ownership structure, including institutional shareholders, insiders, and retail investors. As of September 2025, there were 387 institutional owners and shareholders holding a total of 155,808,032 shares. Major institutional owners include Vanguard Group Inc. and BlackRock, Inc. The largest individual shareholder is Dr. Patrick Soon-Shiong, who owns 70.13 million shares, representing 7.12% of the company. Insiders collectively own approximately 7.76% of the company.